The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of reirradiation combined with pembrolizumab in patients with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck (HNSCC).
 
Dan Paul Zandberg
Consulting or Advisory Role - Bicara Therapeutics; Blueprint Medicines; InhibRx; Macrogenics; Merck; Prelude Therapeutics; Seagen
Research Funding - Aduro Biotech (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); EMD Serono (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Macrogenics (Inst); Merck (Inst); Novasenta (Inst)
 
Jessica R Bauman
Consulting or Advisory Role - EMD Serono; Pfizer
 
Ranee Mehra
Stock and Other Ownership Interests - GlaxoSmithKline (I)
Consulting or Advisory Role - Coherus Biosciences; Janssen Oncology; Merck KGaA
Research Funding - AstraZeneca; Merck
Travel, Accommodations, Expenses - Merck KGaA
(OPTIONAL) Uncompensated Relationships - AstraZeneca
 
Jason K. Molitoris
No Relationships to Disclose
 
Mark Jelinek
No Relationships to Disclose
 
Hong Wang
No Relationships to Disclose
 
David Anthony Clump
No Relationships to Disclose
 
Heath Devin Skinner
No Relationships to Disclose
 
Robert L. Ferris
Stock and Other Ownership Interests - Novasenta
Consulting or Advisory Role - Adagene; Adaptimmune; Aduro Biotech; Bicara Therapeutics; Bristol-Myers Squibb; Cantenion; Coherus Biosciences; CureVac; CytoAgents; Eisai Europe; EMD Serono; Eterna Therapeutics; Everest Clinical Research; F. Hoffmann LaRoche; Federation Bio; Genmab; Genocea Biosciences; Hookipa Pharma; Instil Bio; Kowa Research Institute; Lifescience Dynamics; Macrogenics; MeiraGTx; Merck; Merus NV; Mirati Therapeutics; Mirati Therapeutics; Mirror Biologics; Nanobiotix; Novartis; Novasenta; Numab; OncoCyte; Pfizer; PPD; Rakuten Medical; Regeneron; Sanofi; Seagen; SIRPant Immunotherapeutics; VIR Biotechnology; Zymeworks; Zymeworks
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck; Novasenta; Tesaro
 
Moon Jung Fenton
No Relationships to Disclose
 
Kevin J. Cullen
No Relationships to Disclose
 
Mohan Suntharalingam
No Relationships to Disclose
 
Soren Bentzen
No Relationships to Disclose
 
Anshu Giri
No Relationships to Disclose
 
Jeffrey C Liu
No Relationships to Disclose
 
Thomas James Galloway
Honoraria - UpToDate
Research Funding - Cardinal Health